SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorder

Ann Clin Transl Neurol. 2022 Aug;9(8):1296-1301. doi: 10.1002/acn3.51609. Epub 2022 Jun 17.

Abstract

SARS-COV-2 frequently cause neurological disorders and is sometimes associated with onset of autoimmune diseases affecting the nervous system. Over recent years, a rare but distinct diagnosis designated myelin oligodendrocyte glycoprotein-associated disorder (MOGAD) has been recognized in patients with attacks of optic neuritis, myelitis, or encephalomyelitis and increased levels of anti-MOG antibodies. The cause of MOGAD is unknown. However, there have been reports of single cases of MOGAD in patients with Covid-19 infection. We report a series of SARS-CoV-2 positive patients that developed MOGAD, but a homology search did not support a cross-reactive immune response to SARS-CoV-2 spike-protein and MOG.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • COVID-19*
  • Humans
  • Myelin-Oligodendrocyte Glycoprotein
  • Optic Neuritis*
  • SARS-CoV-2

Substances

  • Autoantibodies
  • Myelin-Oligodendrocyte Glycoprotein

Grants and funding

This work was funded by Edit Jacobson Foundation; Research Foundation of the Multiple Sclerosis Society of Gothenburg; Swedish Federal Government grant LUA/ALF agreement, ALFGBG‐722081; Swedish Society of the Neurologically Disabled.